Actively Recruiting
Evaluating Qishen Yiqi Dripping Pills for Adults with Chronic Heart Failure Due to Coronary Heart Disease Reducing Ejection Fraction
Led by Tasly Pharmaceutical Group Co., Ltd · Updated on 2026-07-07
636
Participants Needed
60
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of Qishen Yiqi Dripping Pills for treating adults aged 18 to 80 with chronic heart failure characterized by reduced ejection fraction due to coronary heart disease, specifically involving Qi deficiency with blood stasis syndrome. This phase 3 trial aims to compare these pills with a placebo to understand their impact on this condition. Participants will receive either Qishen Yiqi Dripping Pills or a matching placebo, both taken orally as 2 bags three times a day, half an hour after meals, over a 12-week period. The study uses a randomized, parallel design with quadruple masking to assess the effects. During the 12 weeks, participants will be monitored through various assessments including the 6-minute walk test, echocardiographic measurements, heart failure symptom evaluations, laboratory tests for biomarkers like NT-proBNP, and quality of life questionnaires. Researchers will track changes from baseline at weeks 4, 8, and 12 to evaluate exercise capacity, symptom improvement, heart function, and safety outcomes throughout the study.
CONDITIONS
Brief Title
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
Research Team
R
Rui Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
